Analytical Quality Control News

Meet the AQCG Board Members at PharmaLab 2024

PharmaLab Congress will take place from 25-27 November 2024 in Düsseldorf/Neuss. This year, the program includes a new track on Analytical Instrument Qualification and System Validation, where several Board members of the ECA Analytical Quality Control Group (AQCG) will be part of the speaker team.

More
Revision of USP Chapter <1033> on Validation of Biological Assays published

Validation of Bioassays - after a rejected attempt to revise Chapter <1033> at the end of 2022, the USP is now publishing a draft revision based on the currently still official version from 2013.

More
Q&As from the Live Online Training "Introduction to the AQCG's new AIQSV Guide" - Part 2

During the ECA Live Online Training "Introduction to the AQCG’s new ECA Guide for an Integrated Lifecycle Approach to Analytical Instrument Qualification and System Validation" on 29 April 2024, many interesting aspects were discussed in the Q&A session. We have compiled a selection of the questions with the teaching team's answers. You can read Part 2 here.

More
Bioactivity Testing for ATMPs

Especially for modern pharmaceutical products such as ATMPs, the development and validation of potency assays is characterised by a number of challenges, which are summarised in the following article ‘Bioactivity testing for ATMPs’.

More
EMA/CMDh: Q&A Document Nitrosamines revised

In July 2024, the nitrosamine Q&A document "Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorization holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products" of the EMA/CMDh was revised again and published on the EMA website under "Questions and answers".

More
EDQM: Availability of Reference Substances

The list of available reference standards is regularly revised and published on the EDQM website. The list comprises more than 3,000 substances, including chemical reference substances, herbal reference standards and biological reference preparations as well as reference spectra for carrying out tests and trials according to Ph. Eur. methods.

More
FDA Warning Letter: Inadequate Lab Testing Procedures

In August 2024, the U.S. FDA issued a Warning Letter (WL) to the Chinese company "Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd." after having inspected its site in December 2023. According to U.S. FDA Warning Letter, the firm failed to implement appropriate release specifications and analytical procedures for some of their drug products.

More
FDA Warning Letter to a Manufacturer of an Athlete Muscle Maintenance Creme

At the beginning of July, the FDA published a Warning Letter due to a lack of chemical and microbiological controls in the manufacture of a product for dermal application and inadequate testing of the ingredients used.

More
FDA Warning Letter - Missing incoming Control Tests

In June 2024, the U.S. FDA issued a Warning Letter to the Portuguese company "Fancystage Unipessoal, LDA" after having inspected its site in January 2024. According to U.S. FDA Warning Letter, the firm failed to do proper incoming control tests to identity the goods.

More
CMDh/EMA: Appendix 1 for Nitrosamines updated again

In July 2024, new substances were added to Appendix 1 of the Nitrosamine Q&A document "Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products" and some existing entries in the list were updated.

More
x
Search